Article
Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin.
European journal of clinical pharmacology - 1 Mar 2013
Quinney Sara K, Malireddy Srikar R, Vuppalanchi Raj, Hamman Mitchell A, Chalasani Naga, Gorski J Christopher, Hall Stephen D
Abstract excerpt
AIMS: To determine the extent and time-course of hepatic and intestinal cytochrome P450 3A (CYP3A) inactivation due to the mechanism-based inhibitor clarithromycin. METHODS: Intestinal and hepatic CYP3A inhibition was examined in 12 healthy volunteers following the administration of single and multiple doses of oral clarithromycin (500 mg). Intestinal biopsies were obtained under intravenous midazolam sedation at...
Topics
- Administration, Oral
- Adult
- Analysis of Variance
- Biopsy
- Biotransformation
- Clarithromycin
- Cytochrome P-450 CYP3A
- Cytochrome P-450 CYP3A Inhibitors
- Drug Administration Schedule
- Duodenum
- Enzyme Inhibitors
- Female
- Genotype